araag2/HINT huggingface dataset:
Clinical trial NCT02255513 (phase 3, status: completed)
Conditions: attention deficit hyperactivity disorder
ICD codes: F90.2, F90.8, F90.9, F90.0, F90.1
Drugs: hld200, placebo
SMILES: COC(=O)C(C1CCCCN1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female children (6-12 years at study entry)

          -  Previous diagnosis of ADHD and confirmation using the Mini International
             Neuropsychiatric Interview for Children and Adolescents (MINI-KID)

          -  Able to swallow treatment capsules

          -  Available for entire study period

          -  Provision of informed consent (from the parent[s] and/or legal representative[s]) and
             assent (from the subject)

          -  Female subjects of childbearing potential (i.e., post-menarche) required to have a
             negative result on urine pregnancy test (and will be given specific instructions for
             avoiding pregnancy during trial).

        Exclusion Criteria:

          -  Any known history or presence of significant cardiovascular, pulmonary, hepatic,
             renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic,
             neurologic, ophthalmologic disease

          -  Presence of any significant physical or organ abnormality

          -  Any illness during the 4 weeks before this study

          -  Comorbid psychiatric diagnosis that may affect subject safety or confound results
             (e.g., psychosis, bipolar disorder)

          -  Known history of severe asthma (in the opinion of the investigator) unless deemed
             currently controlled

          -  Known history of severe allergic reaction to MPH

          -  Known history of seizures (except febrile seizures prior to age 5), anorexia nervosa,
             bulimia or current diagnosis or family history of Tourette's disorder

          -  Subject who are severely underweight or overweight (in the opinion of the
             Investigator)

          -  Any clinical laboratory value outside of the acceptable ranges, unless deemed NCS
             significant per the Investigator

          -  Positive history for hepatitis B, hepatitis C or Human Immunodeficiency Virus (HIV)

          -  Positive screening for illicit drug use, and/or current health conditions or use of
             medications that might confound the results of the study or increase risk to the
             subject

          -  Use of prescription medications (except ADHD medications) within 7 days and
             over-the-counter medications (except birth control) within the 3 days preceding study
             enrollment, unless deemed acceptable by the Investigator and Clinical or Medical
             Monitor

          -  Participation in clinical trial with an investigational drug within the 30 days
             preceding study enrollment

          -  Current suicidal ideation or history of suicidality determined as a significant
             finding on the C-SSRS by the investigator (Baseline C-SSRS for adolescents; Pediatric
             Baseline C-SSRS for children).
Clinical trial NCT02260986 (phase 3, status: completed)
Conditions: atopic dermatitis
ICD codes: L20.89, L20.9
Drugs: dupilumab, placebo (for dupilumab)
SMILES: CCO, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          1. Chronic AD that had been present for at least 3 years before the screening visit;

          2. Documented recent history (within 6 months before the screening visit) of inadequate
             response to a sufficient course of out-patient treatment with topical AD
             medication(s).

        Key Exclusion Criteria:

          1. Participation in a prior Dupilumab clinical trial;

          2. Important side effects of topical medication (e.g. intolerance to treatment,
             hypersensitivity reactions, significant skin atrophy, systemic effects), as assessed
             by the investigator or treating physician;

          3. Having used any of the following treatments within 4 weeks before the baseline visit,
             or any condition that, in the opinion of the investigator, was likely to require such
             treatment(s) during the first 2 weeks of study treatment:

               1. Immunosuppressive/immunomodulating drugs (e.g, systemic steroids, cyclosporine,
                  mycophenolate-mofetil, Janus kinase inhibitors, interferon-gamma [IFN-γ],
                  azathioprine, methotrexate, etc.);

               2. Phototherapy for AD;

          4. Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit;

          5. History of human immunodeficiency virus (HIV) infection or positive HIV serology at
             screening;

          6. Positive hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or
             hepatitis C antibody at the screening visit;

          7. Active or acute infection requiring systemic treatment within 2 weeks before baseline
             visit;

          8. Known or suspected history of immunosuppression;

          9. Pregnant or breastfeeding women, or planning to become pregnant or breastfeed during
             the participant's participation in this study.

        Note: The eligibility criteria listed above is not intended to contain all considerations
        relevant to a participant's potential participation in a clinical trial therefore not all
        inclusion/ exclusion criteria are listed.
Clinical trial NCT02263326 (phase 3, status: completed)
Conditions: hiv infection
ICD codes: Z21
Drugs: dolutegravir, lamivudine, continue current antiretroviral regimen
SMILES: N[C@@H](CO)C(O)=O, CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O, CCO
Eligibility criteria:

        Inclusion Criteria:

          -  HIV-1 Infection

          -  HIV-1 RNA <50 copies/mL on all measurements within 48 weeks prior to study entry while
             on any DHHS recommended or alternative three-drug antiretroviral regimen. (A history
             of switching for simplification and/or tolerability is allowed. At least two
             measurements within the previous 48 weeks are required prior to study screening.)

          -  No history of virologic failure, defined as consecutive HIV RNA > 50 copies/mL after
             12 months of initiating ART. An isolated (non-consecutive) HIV RNA > 50 copies/mL (but
             less than 400 copies/mL) is permitted after 12 months of initiating ART but not in the
             48-week window prior to study entry.

          -  Screening plasma HIV RNA < 20 copies/mL using the COBAS AmpliPrep/COBAS TaqMan HIV-1
             Test V2.0, obtained within 45 days prior to study entry

          -  Nadir CD4 count >200 cells/mm

          -  Pretreatment genotype documenting no mutations in the protease or reverse
             transcriptase genes

          -  No known resistance to integrase inhibitors

          -  Laboratory values obtained within 45 days prior to study entry:

        ANC >750 Hemoglobin >10 g/dL Platelets >50,000 Calculated creatinine clearance (CrCl) >50
        mL/min

          -  Negative serum or urine pregnancy test

          -  Men and women age greater or equal to 18 years.

          -  Ability to continue current regimen (i.e, have uninterrupted access)

          -  No evidence of chronic hepatitis B

        Exclusion Criteria:

          -  Serious illness or AIDS-related complication within 21 days of screening requiring
             systemic treatment and/or hospitalization

          -  Treatment within 30 days prior to study entry with immune modulators

          -  Vaccination within 7 days

          -  Active HCV treatment or anticipated need for treatment within study period. (HCV
             infection alone is not exclusionary)

          -  Unstable liver disease or severe hepatic impairment

          -  Known allergy or hypersensitivity to DTG or lamivudine.

          -  Active drug or alcohol use or dependence that could interfere with adherence to study
             requirements

          -  ALT (alanine aminotransferase) >5 x ULN (upper limit of normal) OR ALT >3 x ULN and
             total bilirubin >1.5 x ULN (with 35% direct bilirubin)
Clinical trial NCT02266849 (phase 3, status: terminated)
Conditions: rectal cancer, ulcerative colitis, short bowel syndrome
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, K51.811, D68.61, D69.41, D81.4, E24.1, E26.01, E26.81, E34.0
Drugs: loperamide, placebo
SMILES: O[Bi]1OC(=O)C2=CC=CC=C2O1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    insuficcient recruiting
  
Eligibility criteria:

        Inclusion Criteria:

          -  Operation for rectal cancer or ulcerative colitis an ileostomy (loop or end ileostomy
             within the last 7 days) OR

          -  ileostomy patient with contact to the stoma clinic OR

          -  Short bowel syndrome with a permanent ileostomy

          -  signed consent form

        Exclusion Criteria:

          -  Complications associated with surgery

          -  Non-radical surgery

          -  Chemotherapy

          -  Poor compliance

          -  Other serious illness
Clinical trial NCT02267343 (phase 3, status: active, not recruiting)
Conditions: gastric cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: ono-4538, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Men & women ≥20 years of age

          -  Unresectable advanced or recurrent gastric cancer (including esophagogastric junction
             cancer)

          -  Histologically confirmed adenocarcinoma

          -  Refractory to or intolerant of standard therapy

          -  ECOG Performance Status score 0 or 1

          -  A life expectancy of at least 3 months

        Exclusion Criteria:

          -  Current or past history of severe hypersensitivity to any other antibody products

          -  Patients with multiple primary cancers

          -  Patients with any metastasis in the brain or meninx that is symptomatic or requires
             treatment

          -  Patients with active, known or suspected autoimmune disease
Clinical trial NCT02268214 (phase 3, status: completed)
Conditions: type 1 diabetes mellitus
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: dapagliflozin, placebo for dapagliflozin
SMILES: CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of Type 1 Diabetes mellitus (T1DM)

          -  Central laboratory C-peptide < 0.7 ng/ml (0.23 nmol/L)

          -  Insulin use for at least 12 months per patient reported or medical records

          -  Method of insulin administration (MDI or CSII) must have been unchanged for at least 3
             months prior to screening

          -  Subjects must be on a total insulin dose of ≥ 0.3 U/kg/day for at least 3 months prior
             to screening

          -  If on MDI insulin administration, subject must be on ≥ 3x injections per day

          -  Screening Visit: Central laboratory HbA1c ≥ 7.7% and ≤ 11.0%

          -  Body mass index (BMI) ≥ 18.5 kg/m2

        Exclusion Criteria:

          -  History of Type 2 Diabetes mellitus (T2DM) or maturity onset diabetes of the young
             (MODY), pancreatic surgery, or chronic pancreatitis that could result in decreased
             beta cell capacity

          -  Taking metformin and/or thiazolidinediones within 2 months prior to screening

          -  Taking any antidiabetic medication (other than insulin), within 1 month prior to
             screening

             - Taking GLP-1 receptor agonist within 2 months prior to screening for once weekly
             administration and within 1 month prior to screening for once or twice daily
             administration

          -  History of diabetes ketoacidosis requiring medical intervention within 1 month prior
             to screening

          -  History of hospital admission for glycemic control (either hyperglycemia or
             hypoglycemia) within 1 month prior to screening

          -  Frequent episodes of severe hypoglycemia (more than one episode requiring medical
             assistance, emergency care), and/or glucagon therapy administered by a third-party
             individual within 1 month prior to screening

          -  History of Addison's disease
Clinical trial NCT02269917 (phase 3, status: completed)
Conditions: human immunodeficiency virus type 1
ICD codes: D84.9, D81.9, D83.9, D84.821, B20, D82.2, D84.822
Drugs: d/c/f/taf, boosted protease inhibitor (bpi), ftc/tdf
SMILES: CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)CN1C=NC2=C(N)N=CN=C12)OC1=CC=CC=C1, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Currently being treated with a stable antiretroviral (ARV) regimen consisting of a
             boosted protease inhibitor (limited to darunavir [DRV] or atazanavir with low-dose
             ritonavir [rtv] or cobicistat [COBI], or lopinavir with rtv) combined with
             emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) only, for at least 6 consecutive
             months preceding the Screening visit

          -  On-treatment plasma human immunodeficiency virus type 1 ribonucleic acid (HIV-1 RNA)
             concentrations less than (<) 50 copies per milliliter (copies/mL) or HIV-1 RNA
             undetectable by a local HIV-1 RNA test between 12 and 2 months prior to the Screening
             visit and have HIV-1 RNA <50 copies/mL at the Screening visit

          -  A single virologic elevation of greater than or equal to (>=) 50 copies/mL after
             previously reaching viral suppression between 12 and 2 months prior to Screening is
             acceptable, provided a subsequent test prior to Screening was <50 copies/mL

          -  Absence of history of failure on DRV treatment and absence of DRV
             resistance-associated mutations (RAMs), if documented historical genotypes are
             available

          -  Normal electrocardiogram (ECG) at Screening (or if abnormal, determined by the
             Investigator to be not clinically significant)

        Exclusion Criteria:

          -  A new acquired immunodeficiency syndrome (AIDS) - defining condition diagnosed within
             the 30 days prior to Screening

          -  Proven or suspected acute hepatitis within 30 days prior to study entry

          -  Hepatitis C antibody positive; however, participants previously cured of hepatitis C
             virus (HCV) infection, with documented sustained virologic response, that is,
             undetectable HCV RNA 24 weeks after the last dose of HCV treatment, are allowed to
             participate

          -  Hepatitis B surface antigen (HBsAg) positive

          -  Participants with cirrhosis as diagnosed based on local practices
Clinical trial NCT02273050 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: saxagliptin 5 mg, placebo 5 mg for saxagliptin, placebo 500 mg for metformin (with titration), metformin 500 mg with titration
SMILES: N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

        1. Subjects with type 2 diabetes mellitus; 2. HbA1c ≥8% but ≤12%; 3.Fasting C-peptide ≥1.0
        ng/ml; 4. Subject will be drug naïve; 5. Body mass index ≤40 kg/m2.

        Exclusion Criteria:

        1. Symptoms of poorly controlled diabetes; 2. Chronic or repeated intermittent
        corticosteroid treatment ; 3. Calculated creatinine clearance <60 ml/min or serum
        creatinine >132.6 μmol/L (>1.5 mg/dL) for men, >123.8 μmol/L (>1.4 mg/dL) for women; 4.
        Creatine Kinase ≥3x ULN; 5.Abnormal TSH value at screening will be further evaluated by
        free T4, subjects with an abnormal free T4 will be excluded; 6. History of administration
        of any antihyperglycaemic therapy for a total of 28 days or for more than three consecutive
        days or a total of seven non-consecutive days during the eight weeks prior to screening; 7.
        Current treatment with a strong CYP3A4/5 inhibitor; 8. Prior treatment with saxagliptin or
        any DPP-4 inhibitor; 9. Significant or history of cardiovascular disease, renal disease,
        psychiatric disorders, Immunocompromised individuals, hemoglobinopathies, liver disease,
        Pancreatitis.
Clinical trial NCT02273180 (phase 3, status: completed)
Conditions: type 1 diabetes mellitus
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: sar342434, humalog, insulin glargine hoe901
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion criteria:

          -  Participants with T1DM diagnosed for at least 12 months and had been treated with
             insulin glargine and Humalog or Novolog®/Novo Rapid® (at least 3 times daily before
             each meal) in the 6 months prior to the screening visit.

          -  Written informed consent.

        Exclusion criteria:

          -  At screening visit, age under legal age of adulthood.

          -  HbA1c <7.0% or >10% at screening.

          -  Diabetes other than T1DM.

          -  Status post pancreatectomy.

          -  Status post pancreas and/or islet cell transplantation.

          -  Pregnancy and lactation.

          -  Women of childbearing potential not protected by highly effective contraceptive method
             of birth control.

          -  Less than 1 year on continuous insulin treatment.

          -  Use of insulin pump in the last 6 months before screening visit.

          -  Use of glucose lowering treatments other than insulin including non-insulin injectable
             peptides in the last 6 months prior to screening visit.

          -  Use of insulin other than insulin glargine and Humalog or Novolog/Novo Rapid as part
             of a multiple injection regimen (3 to 4 injections per day) in the last 6 months
             before screening visit. Liprolog® is a European Union approved insulin lispro and is
             allowed in those countries where it is marketed.

          -  Hospitalization for diabetic ketoacidosis in the last 6 months before screening visit.

          -  Unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic
             retinopathy or macular edema likely to require treatment (eg, laser, surgical
             treatment, or injectable drugs) during the study period.

        The above information is not intended to contain all considerations relevant to a
        participant's potential participation in a clinical trial.
Clinical trial NCT02274558 (phase 3, status: completed)
Conditions: tardive dyskinesia
ICD codes: K22.4, G24.01
Drugs: nbi-98854, placebo
SMILES: COC1=C(OC)C=C2[C@H]3C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN3CCC2=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Subjects of childbearing potential must agree to use hormonal or two forms of
             nonhormonal contraception (dual contraception) consistently during the screening,
             treatment and follow-up periods of the study.

          2. Female subjects must not be pregnant.

          3. Have one of the following clinical diagnoses for at least 3 months prior to screening:
             Schizophrenia or Schizoaffective Disorder, or Mood Disorder.

          4. Have a clinical diagnosis of neuroleptic-induced TD for at least 3 months prior to
             screening.

          5. Have moderate or severe TD.

          6. If using maintenance medication(s) for schizophrenia or schizoaffective disorder, or
             mood disorder, be on stable doses.

          7. Be in good general health.

          8. Have adequate hearing, vision, and language skills to perform the procedures specified
             in the protocol.

          9. Have a negative drug screen for amphetamines,barbiturates, benzodiazepines,
             phencyclidine, cocaine, opiates, or cannabinoids

        Exclusion Criteria:

          1. Have an active, clinically significant unstable medical condition within 1 month prior
             to screening.

          2. Have a known history of substance dependence, or substance (drug) or alcohol abuse

          3. Have a significant risk of suicidal or violent behavior.

          4. Have a known history of neuroleptic malignant syndrome.

          5. Have a known history of long QT syndrome or cardiac tachy-arrhythmia.

          6. Have a cancer diagnosis within 3 years of screening (some exceptions allowed)

          7. Have received an investigational drug within 30 days prior to screening or plan to use
             an investigational drug (other than NBI-98854) during the study.

          8. Have a blood loss ≥550 mL or donated blood within 30 days prior to Baseline.

          9. Have an allergy, hypersensitivity, or intolerance to tetrabenazine.

         10. Have had previous exposure with NBI-98854 or had previously participated in an
             NBI-98854 clinical study.

         11. Are currently pregnant or breastfeeding.